Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study

scientific article published on September 2013

Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1310/HCT1403-204
P698PubMed publication ID24144897

P50authorFederico PulidoQ45357574
Joaquín PortillaQ56449004
José Ramón BlancoQ57423022
Julian OlallaQ74043055
Alberto Romero PalaciosQ81565702
P2093author name stringMelchor Riera
Francisco Vera
Pere Domingo
Juan Luis Gómez-Sirvent
Piedad Arazo
Koldo Aguirrebengoa
Ana María Caro-Murillo
Enric Pedrol
Manuel Angel Castaño
Pedro Ferrer
P2860cites workLife expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesQ24597052
A new equation to estimate glomerular filtration rateQ24651973
Prevalence and factors associated with renal dysfunction among HIV-infected patientsQ30484533
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyQ33565604
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyQ33689432
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.Q34289633
Neuropsychiatric complications of antiretroviral therapyQ34565848
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy oQ35000905
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directionsQ35088160
A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United StatesQ35872422
Treatment of HIV infection in the older patientQ35917538
Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactionsQ36342389
Medication compliance and persistence: terminology and definitionsQ37072950
Pharmacologic consideration for the use of antiretroviral agents in the elderlyQ37277510
Spectrum of chronic kidney disease in HIV-infected patients.Q37396053
Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.Q38958723
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT studyQ42658845
The impact of gender and anchor drugs on TDF renal toxicityQ42880491
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patientsQ43044739
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, FranceQ43225383
HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, SpainQ43237663
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York CityQ45730280
Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapyQ45732541
Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.Q46053873
Older age and the response to and tolerability of antiretroviral therapyQ46177165
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapyQ46432681
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.Q46900196
Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapyQ46943637
Premature age-related comorbidities among HIV-infected persons compared with the general population.Q51000618
Chronic renal failure among HIV-1-infected patients.Q51914547
P433issue5
P921main subjecttenofovirQ155954
emtricitabineQ422604
P304page(s)204-215
P577publication date2013-09-01
P1433published inHIV Clinical TrialsQ15756361
P1476titleSafety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study
P478volume14

Reverse relations

Q41428022Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP studycites workP2860

Search more.